Publications by authors named "Torsten Skov"

Claim this Profile
E
Efficacy and safety of ingenol disoxate gel in field treatment of actinic keratosis on full face, scalp or large area (250 cm2) on the chest: results of four phase 3 randomized controlled trials.
Brian Berman, Michael Bukhalo, C William Hanke, Mikala Fiig Jarner, Thomas Larsson, Torsten Skov

Dermatol Online J· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ingenol mebutate gel in field treatment of actinic keratosis on full face, balding scalp, or approximately 250 cm on the chest: A phase 3 randomized controlled trial.
C William Hanke, Lorne Albrecht, Torsten Skov, Thomas Larsson, Marie Louise Østerdal

J Am Acad Dermatol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population.
Birgit Guldhammer Skov, Sara Bird Rørvig, Thomas Hartvig Lindkær Jensen, Torsten Skov

Mod Pathol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy Endpoints in Clinical Trials in Actinic Keratosis.
Torsten Skov, Eggert Stockfleth, Rolf-Markus Szeimies, Brian Berman

Dermatol Ther (Heidelb)· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of Ingenol Disoxate Gel Administered Under Maximum-Use Conditions to Patients With Actinic Keratosis.
Edward Lain, Torsten Skov, Anders Hall

Clin Drug Investig· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx.
Birgit G Skov, Torsten Skov

Appl Immunohistochem Mol Morphol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Escalating Doses of Ingenol Mebutate for Field Treatment of Actinic Keratosis on the Full Face, Full Balding Scalp, or Chest.
C William Hanke, Brian Berman, Neil Swanson, David M Pariser, Jonathan S Weiss, Torsten Skov

J Drugs Dermatol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regression Analysis of Local Skin Reactions to Predict Clearance of Actinic Keratosis on the Face in Patients Treated With Ingenol Mebutate Gel: Experience from Randomized Controlled Trials.
Shelbi Jim On, Kim Mark Knudsen, Torsten Skov, Mark Lebwohl

J Drugs Dermatol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Squamous cell carcinoma and keratoacanthomas are biologically distinct and can be diagnosed by light microscopy: a review.
Johan Selmer, Torsten Skov, Lynda Spelman, David Weedon

Histopathology· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological Effects of Ingenol Mebutate Gel in Moderate to Severe Actinic Fields Assessed by Reflectance Confocal Microscopy: A Phase I Study.
Martina Ulrich, Susanne Lange-Asschenfeldt, Kresten Skak, Torsten Skov, Marie Louise Østerdal

J Drugs Dermatol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between severity of the local skin reactions and the rate of local skin reaction resolution in patients treated with ingenol mebutate gel.
Shelbi C Jim On, Kim Mark Knudsen, Torsten Skov, Mark Lebwohl

Clin Cosmet Investig Dermatol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population.
Birgit G Skov, Estrid Høgdall, Paul Clementsen, Mark Krasnik, Klaus Richter Larsen, Torsten Skov

APMIS· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results.
Brian Berman, Gary Goldenberg, C William Hanke, Stephen K Tyring, Wm Philip Werschler, Torsten Skov

J Drugs Dermatol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
Birgit Guldhammer Skov, Bente Holm, Anders Erreboe, Torsten Skov, Anders Mellemgaard

J Thorac Oncol· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine.
Bente Holm, Anders Mellemgaard, Torsten Skov, Birgit Guldhammer Skov

J Clin Oncol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reclassification of neuroendocrine tumors improves the separation of carcinoids and the prediction of survival.
Birgit Guldhammer Skov, Mark Krasnik, Sylvie Lantuejoul, Torsten Skov, Elisabeth Brambilla

J Thorac Oncol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I study of CHS 828 in patients with solid tumor malignancy.
Peter Hovstadius, Rolf Larsson, Elin Jonsson, Torsten Skov, Anne-Marie Kissmeyer

Clin Cancer Res· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis